1. |
赵靖平, 施慎逊. 中国精神分裂症防治指南(第二版). 北京: 中华医学电子音像出版社, 2015.
|
2. |
黄源, 刘国恩, 刘跃华, 等. 精神分裂症的疾病经济负担: 基于广州医保数据的分析. 中国卫生经济, 2014, 33(5): 62-65.
|
3. |
Phillips D. Quality of life: concept, policy and practice. Oxfordshire: Routledge, 2006.
|
4. |
王倩, 林果为, 徐三荣. 慢性胃炎, 消化性溃疡和胃癌的健康效用值的测定. 中华消化杂志, 2000, 20(4): 273-274.
|
5. |
Deummonnd MF, O' brien BJ, Stoddart GL, et al. Methods for economic evaluation of health care programmes (2nd editon). Oxford: Oxford University Press, 1997.
|
6. |
官海静, 刘国恩. 中国四地城乡居民生命质量的比较分析. 中国卫生经济, 2015, 34(2): 5-12.
|
7. |
Aceituno D, Pennington M, Iruretagoyena B, et al. Health state utility values in schizophrenia: a systematic review and meta-analysis. Value Health, 2020, 23(9): 1256-1267.
|
8. |
Papaioannou D, Brazier J, Paisley S. NICE DSU technical support document 9: the identification, review and synthesis of health state utility values from the literature. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425822/pdf/Bookshelf_NBK425822.pdf.
|
9. |
Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health, 2019, 22(3): 267-275.
|
10. |
张天嵩, 董圣杰, 周支瑞. 高级 Meta 分析方法: 基于Stata实现. 上海: 复旦大学出版社, 2015.
|
11. |
Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care, 2000, 38(10): 1011-1021.
|
12. |
Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics, 2000, 17(3): 273-286.
|
13. |
Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ, 2001, 4(1-4): 137-156.
|
14. |
Kasckow JW, Twamley E, Mulchahey JJ, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res, 2001, 103(1): 69-78.
|
15. |
Dernovsek MZ, Prevolnik Rupel V, Rebolj M, et al. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry, 2001, 16(8): 474-482.
|
16. |
Prieto L, Sacristán JA. What is the value of social values. The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol, 2004, 4: 10.
|
17. |
van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res, 2005, 14(2): 441-451.
|
18. |
Luo N, Seng BK, Thumboo J, et al. A study of the construct validity of the health utilities index mark 3 (HUI3) in patients with schizophrenia. Qual Life Res, 2006, 15(5): 889-898.
|
19. |
Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes, 2008, 6: 105.
|
20. |
König HH, Günther OH, Angermeyer MC, et al. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics, 2009, 27(5): 405-419.
|
21. |
McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ, 2009, 12(1): 27-31.
|
22. |
Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the schizophrenia health outcomes (SOHO) study. Value Health, 2009, 12(4): 536-543.
|
23. |
Thwin SS, Hermes E, Lew R, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the quality of well-being scale and disease-specific measures. Psychiatry Res, 2013, 209(3): 291-296.
|
24. |
Millier A, Amri I, Boyer L, et al. Utility decrements associated with side effects in schizophrenia. J Med Econ, 2014, 17(12): 853-861.
|
25. |
Wijnen BFM, Pos K, Velthorst E, et al. Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. PLoS One, 2018, 13(11): e0206236.
|
26. |
Holt RI, Hind D, Gossage-Worrall R, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess, 2018, 22(65): 1-160.
|
27. |
Abdin E, Chong SA, Seow E, et al. A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore. Psychiatry Res, 2019, 274: 400-408.
|
28. |
Chan HY, Wijnen BFM, Hiligsmann M, et al. Assessment of quality of life 8-dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia. Expert Rev Pharmacoecon Outcomes Res, 2022, 22(5): 795-803.
|
29. |
Purba FD, Anggriani Y, Murtini T. EQ-5D-5L in schizophrenia: differences between patients and nurses' reports. Health Qual Life Outcomes, 2021, 19(1): 240.
|
30. |
Spilker B. Quality of life and pharmacoeconomics in clinical trials (2nd edition). New York: Raven Press, 1996.
|
31. |
Versteegh MM, Vermeulen KM, Evers SM, et al. Dutch tariff for the five-level version of EQ-5D. Value Health, 2016, 19(4): 343-352.
|
32. |
Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ, 2018, 27(1): 7-22.
|
33. |
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ, 2002, 21(2): 271-292.
|
34. |
van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 2012, 15(5): 708-715.
|
35. |
Luo N, Wang P, Thumboo J, et al. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics, 2014, 32(5): 495-507.
|
36. |
Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes, 2003, 1: 54.
|
37. |
Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ, 2006, 15(10): 1121-1132.
|
38. |
Richardson J, Sinha K, Iezzi A, et al. Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res, 2014, 23(8): 2395-2404.
|
39. |
Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy, 2017, 15(2): 127-137.
|
40. |
Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ, 2010, 11(2): 215-225.
|
41. |
Earnshaw J, Lewis G. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics, 2008, 26(9): 725-727.
|
42. |
任雪英, 张建方, 占建华, 等. 社会心理干预对精神分裂症患者药物治疗的成本-效果分析. 医院管理论坛, 2019, 36(9): 38-40,15.
|
43. |
朱晓晨, 陈彦瑾, 韩晟. 哌罗匹隆治疗精神分裂症的药物经济学评价——基于主要不良事件的研究. 中国药房, 2021, 32(10): 1252-1256.
|
44. |
刘凤斌, 赵利, 郎建英, 等. 中华生存质量量表的研制. 中国组织工程研究与临床康复, 2007, (52): 10492-10495,10515.
|
45. |
Ng SM, Yau JK, Chan CL, et al. The measurement of body-mind-spirit well-being toward multidimensionality and transcultural applicability. Soc Work Health Care, 2005, 41(1): 33-52.
|